Cancer Treatment

World

Student Faces Deportation from UK After Pro-Palestine Protests, Citing 'Authoritarian' Echoes

Usama Ghanem, an Egyptian student at King's College London, faces imminent deportation after disciplinary action linked to his pro-Palestinian activism. He claims the university's response mirrors the political persecution he fled in Egypt, raising urgent questions about academic freedom and the treatment of international dissent.

Jan 30, 2026

Business

Genmab Shares Face Target Cut After EPKINLY Trial Misses Survival Goal, But Analysts Keep Faith

H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.

Jan 30, 2026

Business

Bank of America Lifts Target on Xencor Amid Broader Biotech Sector Optimism

Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.

Jan 30, 2026

Business

Nuvation Bio's Ibtrozi Gains Favor on Strong Launch, Truist Raises Target

Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.

Jan 30, 2026

Business

UBS Bets Big on Biotech Turnaround, Initiates Arcellx Coverage with $100 Target

UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.

Jan 30, 2026

GeneDx CEO on a Mission: Ending the 'Diagnostic Odyssey' for Rare Diseases

In an exclusive interview, GeneDx CEO Katherine Stueland details how rapid genomic testing is transforming pediatric care, slashing diagnosis times from years to days and building a data-driven bridge to future therapies.

Feb 2, 2026

Business

Simon Property Group Caps Strong Year with Record FFO, Outlines Aggressive $4B+ Redevelopment Pipeline

Simon Property Group reported robust fourth-quarter results, driven by record funds from operations and resilient leasing demand. The retail REIT giant is steering a multi-billion dollar redevelopment strategy while returning significant capital to shareholders, even as it navigates a cautious outlook for 2026.

Feb 2, 2026

Business

Hussman Strategic Advisors Exits Position in Biotech Firm TG Therapeutics

Investment firm Hussman Strategic Advisors has liquidated its entire stake in TG Therapeutics, a move that comes as the biotech's stock lags behind broader market gains despite reporting strong revenue growth for its flagship product.

Feb 2, 2026

World

Turin Erupts in Violence as Anarchist Clashes Leave Over 100 Police Injured; Meloni Vows Crackdown

Weekend protests in Turin descended into severe violence, with anarchist and far-left groups clashing with police, resulting in over 100 officer injuries. Prime Minister Giorgia Meloni condemned the "attempted murder" and promised a firm state response.

Feb 2, 2026

Business

RoundTable Healthcare Partners Acquires Colorescience, Bolstering Portfolio with Fast-Growing Skincare Brand

Private equity firm RoundTable Healthcare Partners has acquired the dermatologist-trusted skincare and sun protection brand Colorescience from 1315 Capital, as the company's annual sales approach the $100 million mark.

Feb 2, 2026

Business

DaVita Posts Strong Q4 Earnings, Fueling Investor Optimism Amid Healthcare Sector Scrutiny

DaVita Inc. (NYSE: DVA) reported fourth-quarter revenue and profit that surpassed analyst forecasts, driven by strategic pricing and operational efficiency. The results sent shares sharply higher as the dialysis giant navigates a complex regulatory and demographic landscape.

Feb 2, 2026

US

Pennsylvania Woman Charged with Arson After Allegedly Setting Duplex Ablaze Following Breakup

A 25-year-old Johnstown woman faces 18 felony counts, including arson endangering lives, after investigators say she intentionally set a duplex fire that forced residents to leap from second-story windows to escape.

Feb 2, 2026

Business

Erasca Soars 460% in a Year: A Biotech Bet Riding on Hope and High Stakes

Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.

Feb 2, 2026

Business

Novo Nordisk Advances Oral Obesity Pill and Cell Therapy Pipeline Amid Market Reassessment

Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.

Feb 2, 2026

Business

Cramer Cools on Novo Nordisk: 'It's a Hold, Not a Buy' After Stellar Run

CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.

Feb 2, 2026

Business

Beyond the Scale: How the GLP-1 Boom is Reshaping Diets, Wallets, and Industries

The surge in popularity of weight-loss drugs like Ozempic and Wegovy is sending shockwaves far beyond the pharmacy, fundamentally altering consumer spending, challenging major corporations, and forcing a broad economic recalibration.

Feb 2, 2026

Business

Beyond the GLP-1 Hype: Is Novo Nordisk's Diversified Pipeline Its Hidden Strength?

While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.

Feb 2, 2026

US

Pennsylvania Unites in Defense of Punxsutawney Phil as PETA's Hologram Proposal Meets Bipartisan Backlash

In a rare show of unity, Pennsylvania's political leaders from both parties are rallying behind the state's famed weather-predicting groundhog, pushing back against an animal rights group's call to replace the living animal with a digital projection.

Feb 2, 2026

Business

FDA Delays Aquestive's Anaphylm Epinephrine Film, Demands Human Factors Revisions

The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.

Feb 2, 2026

Business

Beyond the Rally: Three Tech Stocks Poised for Growth in a Volatile 2026 Market

As major indices climb, investors are sifting through economic crosscurrents to find resilient tech innovators. We examine three companies—Veracyte, monday.com, and Zeta Global—whose strategic moves and financial momentum position them for potential growth.

Feb 2, 2026